Transforming Translation Through Quantitative Pharmacology for High-Impact Decision Making in Drug Discovery and Development
Clin Pharmacol Ther
.
2020 Jun;107(6):1285-1289.
doi: 10.1002/cpt.1667.
Epub 2019 Nov 10.
Authors
Neeraj Gupta
1
,
Dean Bottino
1
,
Ulrika S H Simonsson
2
,
Cynthia J Musante
3
,
Tjerk Bueters
4
,
Theodore R Rieger
3
,
Sreeraj Macha
5
,
Marylore Chenel
6
,
Craig Fancourt
4
,
Jitendra Kanodia
7
,
Satyaprakash Nayak
3
Affiliations
1
Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachusetts, USA.
2
Uppsala University, Uppsala, Sweden.
3
Pfizer Inc, Cambridge, Massachusetts, USA.
4
Merck & Co., Inc, Kenilworth, New Jersey, USA.
5
Sanofi, Bridgewater, New Jersey, USA.
6
Servier, Suresnes, France.
7
Theravance Biopharma US, Inc., South San Francisco, California, USA.
PMID:
31709519
DOI:
10.1002/cpt.1667
No abstract available
MeSH terms
Decision Making
Drug Development / methods*
Drug Discovery / methods*
Humans
Pharmacology
Translational Research, Biomedical / methods*